EUVIMEDEUVIMED entdecken
Systematische ÜbersichtNetzwerk-Metaanalyse

Efficacy of medical treatment on acromegaly based on biochemical and radiological response: a systematic review and network meta-analysis

Chrysi K. Kaparounaki

Aristotle University of Thessaloniki · 01.01.2023

DOI: 10.26262/heal.auth.ir.351409 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Aristotle University of Thessaloniki, erschienen am 01.01.2023. Verfasst von Chrysi K. Kaparounaki.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acromegaly is a rare disorder resulting from a growth hormone-secreting pituitary adenoma. Clinical trial evidence for the management of acromegaly is scarce. The aim of the study was to compare treatments for acromegaly through a network meta-analysis, in terms of biochemical and radiological responses. This thesis reports outcomes only for high-level evidence, randomized trials. A systematic review and network meta-analysis was conducted according to the preferred reporting items for systematic reviews and network meta-analyses (PRISMA) guidelines and Cochrane Handbook assistance (PROSPERO registration: CRD 42023364373). Electronic databases, including PubMed (MEDLINE), Scopus, Web of Science and grey literature, were searched. The initial search included randomized, non-randomized trials and observational studies, evaluating the efficacy or safety of acromegaly treatments. Primary outcomes were the percentage of adjusted insulin-like growth factor 1 (IGF-1) normalization and tumor shrinkage. All statistical analysis was performed using the R software. The search identified 5,584 study reports. The systematic review included 11 randomized controlled trials, 10 of which contributed to network meta-analysis. Treatment ranking showed that pasireotide LAR and co-treatment of octreotide LAR with pegvisomant had the highest probabilities of being the best treatments (61.0% and 25.9%, respectively) for the outcome of adjusted IGF-1 normalization, and placebo had the best probability (80.7%) of being the worst treatment option. Pasireotide LAR was better than octreotide LAR (OR 3.86; 95% CIs 1.03 to 14.51) and oral octreotide capsules (OR 18.11; 95% CIs 1.27 to 258.92) for the same outcome of interest with a moderate amount of inconsistency (I2=63.8%). No important safety outcomes were observed. A meta-analysis was feasible for the outcome of adjusted IGF-1 normalization. Our findings support current evidence and propose the consideration of pasireotide LAR and combination treatments as alternative treatment options. Other parameters, such as cost and safety outcomes should be considered. The study received no funding.

Schlagwörter

acromegalygrowth hormone-secreting pituitary adenomaoctreotide LARpegvisomantIGF-1 normalizationtumor shrinkagesomatostatin analoguestreatment efficacy comparison

Zitieren

APA

Kaparounaki, C. K. (2023). Efficacy of medical treatment on acromegaly based on biochemical and radiological response: a systematic review and network meta-analysis. Aristotle University of Thessaloniki. https://doi.org/10.26262/heal.auth.ir.351409

Vancouver

Kaparounaki CK. Efficacy of medical treatment on acromegaly based on biochemical and radiological response: a systematic review and network meta-analysis. Aristotle University of Thessaloniki. 2023. doi:10.26262/heal.auth.ir.351409

BibTeX
@article{Kaparounaki2023,
  author = {Kaparounaki, Chrysi K.},
  title = {Efficacy of medical treatment on acromegaly based on biochemical and radiological response: a systematic review and network meta-analysis},
  journal = {Aristotle University of Thessaloniki},
  year = {2023},
  doi = {10.26262/heal.auth.ir.351409}
}
Kostenlos starten →